Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-06

Clinical Trial Update: Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) [Phase 1]

View source ↗

Summary

Phase 1 trial updating safety and immunogenicity of MV-ZIKA-RSP vaccine (V187-001) for Zika virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MV-ZIKA-RSP

Snippet

Sponsor: Themis Bioscience GmbH | Conditions: Zika Virus Infection | Phase 1 | Status: COMPLETED | Results posted: 2021-12-06